CytoDyn Inc.

CytoDyn Inc.

CYDY - Insider Information

Get informed when a big investor buys or sells

+ Follow
Market Cap$306.85M
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
CytoDyn Inc.CytoDyn Inc.-5.6-58%--0.4
$-0.02

Current Fair Value

109.2% downside

Overvalued by 109.2% based on the discounted cash flow analysis.

Insider Trades

Loading insider trades…

Congress Trades

Loading congress trades…

Share Statistics

Market cap$306.85 Million
Enterprise Value$326.35 Million
Earnings per Share$-0.03
Beta1.24
Outstanding Shares1,382,223,000

Return

Return on Equity58.22%ROE
Return on Assets-299.65%
Return on Invested Capital134.74%

Valuation & Multiples

P/E Ratio-5.64P/E Ratio
PEG-2.17PEG
Price to Sales-Price to Sales
Price to Book Ratio-0.22Price to Book Ratio
Enterprise Value to Revenue-
Enterprise Value to EBIT-7.9
Enterprise Value to Net Income-6
Total Debt to Enterprise0.11
Debt to Equity-0.37Debt to Equity

Revenue Sources

No data

Last Earnings Call

Report Date
October 15, 2026
EPS Estimate
-$0.05
Consensus analyst estimate
Revenue Estimate
-
Consensus analyst estimate

Next Earnings Call

Expected Date
January 14, 2027
EPS Estimate
-$0.05
Consensus analyst estimate
Revenue Estimate
-
Consensus analyst estimate

Institutional Put/Call Ratio

Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.

Put/Call Ratio0.00000%
Total Calls-
Total Puts-

Institutional Ownership

Holdings and activity of institutional investors.

Ownership %0.01%▼ 0.00%
Total Invested$19,657▼ 44.18%
Investors Holding5▼ 1.00%

About CytoDyn Inc.

14 employees
CEO: Jacob Lalezari

CytoDyn Inc. functions as a biotechnology enterprise currently in its clinical development phase. The company primarily concentrates on crafting therapies for a variety of medical conditions, leveraging leronlimab – an innovative humaniz...